Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > ORGANIZATION
ORGANIZATION
- Keidanren Wades into Pricy Med Debate, Calls for Quick Price Review
October 17, 2016
- Govt and Industry Should Generate Ideas Together: EFPIA Japan Chief
October 7, 2016
- Value of Pharmaceutical Innovation Should Be Fully Recognized: PhRMA CEO
September 30, 2016
- Generic Use Rate at 60.1% in April-June: JGA
September 30, 2016
- Japan Wholesaler Chief Suzuki to Become IFPW Vice Chairman
September 16, 2016
- Japan Needs Listing Rule Conditional on Possible Ad-Hoc Re-Pricing: Kono
September 7, 2016
- Kenporen’s Kono Pushes for “Huge Seller” Re-Pricing for Opdivo before 2018
September 7, 2016
- Hodanren Demands Ad-Hoc Re-Pricing for Opdivo
September 7, 2016
- Economists, Industry and Regulatory Officials Talk over Pricy Med Issue at JPMA Seminar
September 6, 2016
- JMA Think Tank Calls for Rewarding Innovation with Subsidies, in Lieu of Pricing
September 1, 2016
- Drug Wholesalers See 8.3% Boost in Sales on Hep C Demand: JPWA
August 17, 2016
- JPMA Calls for Financial Support to Encourage R&D on Treatments for ARIs
August 15, 2016
- Sales Rep Number in Japan Logs Big Drop for 2nd Straight Year: Survey
August 12, 2016
- EFPIA Japan Calls for Relaxation of Japanese Vaccine Regulations: Vaccine Subcommittee Head
August 9, 2016
- NPO Petitions Academic Society to Clarify Reason for Deaths Associated with Xeplion
July 20, 2016
- Japan Biosimilar Association Up and Running with Four Member Firms
July 19, 2016
- JPMA Keen to Defend R&D Tax Credit System
July 8, 2016
- Generic Use Rate at 55.7% in FY2015, Up 3.7 Points: JGA
July 8, 2016
- EFPIA Japan Calls for Diversifying Vaccine Supply Sources to Prepare for Crises
July 7, 2016
- Drug Damage Watchdog Challenges Doctors’ View, Says HPV Vaccination Shouldn’t Be Recommended
July 5, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…